Actinogen Medical (ACW) Price & Analysis

Compare

37 Followers

ACW Stock Chart & Stats

AU$0.04

>-AU$0.01(-3.85%)

At close: Jan 09 4:00 PM EST

AU$0.04

>-AU$0.01(-3.85%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.07

Previous CloseN/A

Volume244.11K

Average Volume (3M)6.03M

Market Cap

AU$141.94M

Enterprise ValueAU$128.69M

Total Cash (Recent Filing)AU$16.50M

Total Debt (Recent Filing)AU$3.26M

Price to Earnings (P/E)―

Beta-0.41

Next Earnings

Feb 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding3,461,912,000

10 Day Avg. Volume4,755,726

30 Day Avg. Volume6,028,147

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)3.74

Price to Sales (P/S)12.48

P/FCF Ratio-9.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.08

Price Target Upside100.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)AU$16.59M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Moderate Balance SheetA low debt-to-equity profile and a moderate balance-sheet position give the company durable financial flexibility. This reduces solvency risk, preserves capacity to fund clinical programs or absorb setbacks without immediate debt pressure, and supports longer R&D timelines.

High Gross Profit MarginA reported 100% gross margin indicates negligible COGS today, consistent with a clinical-stage biotech. If xanamem or other assets commercialize, the structural cost profile could support attractive product-level economics, helping long-term margin sustainability once revenues scale.

Focused Pipeline And Lead CandidateA clear R&D focus around xanamem and a defined mechanism (11β-HSD1 inhibition) gives strategic clarity and helps concentrate resources. This focused pipeline can improve trial execution, attract specialized partners, and create a differentiated clinical value proposition in neuropsychiatric/neurodegenerative markets.

Bears Say

Declining Revenue And Persistent LossesA steep revenue decline combined with sustained negative net, EBIT and EBITDA margins signals structural profitability issues. Over the medium term this undermines internal funding for trials, increases reliance on external capital, and makes it harder to demonstrate financial sustainability to stakeholders.

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow, with declining FCF growth, indicate an ongoing cash burn. That creates durable financing risk, likely necessitating equity or debt raises that dilute shareholders or constrain strategic options, and can delay or limit clinical development cadence.

Clinical-stage, No Commercialization YetBeing pre-commercial means revenue is limited and outcomes are binary and regulatory dependent. This structural business risk requires sustained capital and exposes the company to trial failures or delays that can materially impair value and extend the timeline to profitable operations.

Actinogen Medical News

Actinogen boosts cash reserves with additional A$1.9m R&D tax rebate

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has received a further A$1.87...

6d ago

Actinogen Medical launches $5m digital-only share purchase plan for retail investors

Actinogen Medical ( ($AU:ACW) ) has provided an update. Actinogen Medical has launched a share purchase plan offering...

7d ago

Actinogen launches discounted share purchase plan to fund Alzheimer’s trial

An announcement from Actinogen Medical ( ($AU:ACW) ) is now available. Actinogen Medical has launched a share purchase...

7d ago

Actinogen Raises Capital via Institutional Share Placement to Support Late-Stage Trials

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has raised capital by issuing...

8d ago

Actinogen Seeks ASX Quotation for 269.8 Million New Shares

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has applied to the ASX...

8d ago

Actinogen Medical Seeks ASX Quotation for 190,228 New Shares

Actinogen Medical ( ($AU:ACW) ) has shared an update. Actinogen Medical has applied for quotation on the ASX...

12d ago

Actinogen Medical Launches Securities Purchase Plan for Up to 119 Million New Shares

An update from Actinogen Medical ( ($AU:ACW) ) is now available. Actinogen Medical has announced a proposed issue...

15d ago

Actinogen Medical Plans Equity Issue of Up to 15.9 Million Shares

Actinogen Medical ( ($AU:ACW) ) has provided an announcement. Actinogen Medical has notified the ASX of a proposed...

15d ago

Actinogen Medical Plans Major Share Placement to Issue Up to 270 Million Shares

An announcement from Actinogen Medical ( ($AU:ACW) ) is now available. Actinogen Medical Limited has announced a proposed...

15d ago

Actinogen Raises Up to A$17m to Fund Pivotal Alzheimer’s Trial Through to Final Results

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has secured firm commitments for...

15d ago

ACW FAQ

What was Actinogen Medical Limited’s price range in the past 12 months?

Actinogen Medical Limited lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.

What is Actinogen Medical Limited’s market cap?

Actinogen Medical Limited’s market cap is AU$141.94M.

When is Actinogen Medical Limited’s upcoming earnings report date?

Actinogen Medical Limited’s upcoming earnings report date is Feb 19, 2026 which is in 2 days.

How were Actinogen Medical Limited’s earnings last quarter?

Actinogen Medical Limited released its earnings results on Aug 25, 2025. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.

Is Actinogen Medical Limited overvalued?

According to Wall Street analysts Actinogen Medical Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Actinogen Medical Limited pay dividends?

Actinogen Medical Limited does not currently pay dividends.

What is Actinogen Medical Limited’s EPS estimate?

Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Actinogen Medical Limited have?

Actinogen Medical Limited has 3,461,912,000 shares outstanding.

What happened to Actinogen Medical Limited’s price movement after its last earnings report?

Actinogen Medical Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.

Which hedge fund is a major shareholder of Actinogen Medical Limited?

Currently, no hedge funds are holding shares in AU:ACW

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Actinogen Medical Stock Smart Score

Neutral

Fundamentals

Return on Equity

-75.99%

Trailing 12-Months

Asset Growth

12.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Actinogen Medical Limited

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Actinogen Medical (ACW) Earnings & Revenues

Historic Earnings Reports

ACW Stock 12 Month Forecast

Average Price Target

AU$0.08

▲(100.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.044,0.046769230769230764,0.04953846153846154,0.052307692307692305,0.05507692307692308,0.057846153846153846,0.06061538461538461,0.06338461538461539,0.06615384615384615,0.06892307692307692,0.0716923076923077,0.07446153846153847,0.07723076923076923,{"y":0.08,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.044,0.046769230769230764,0.04953846153846154,0.052307692307692305,0.05507692307692308,0.057846153846153846,0.06061538461538461,0.06338461538461539,0.06615384615384615,0.06892307692307692,0.0716923076923077,0.07446153846153847,0.07723076923076923,{"y":0.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.044,0.046769230769230764,0.04953846153846154,0.052307692307692305,0.05507692307692308,0.057846153846153846,0.06061538461538461,0.06338461538461539,0.06615384615384615,0.06892307692307692,0.0716923076923077,0.07446153846153847,0.07723076923076923,{"y":0.08,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.027,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.034,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.027,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.023,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.025,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.028,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.035,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.059,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.061,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.044,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >